Floege, J., Gibson, K. L., Vivarelli, M., Liew, A., Radhakrishnan, J., Balk, E. M., Gordon, C. E., Adam, G., Tonelli, M., Earley, A., & Rovin, B. H. (2025). Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney International, 107(5), 806–808. https://doi.org/10.1016/j.kint.2024.11.006

Tarragón, B., Han, H., Navarro-Torres, M., Canetta, P., Wooden, B., Derebail, V. K., Glenn, D., Mottl, A., Massicotte-Azarniouch, D., Kerlin, B., Hladunewich, M., Coppock, G., Rheault, M., Mariani, L. H., & Bomback, A. (2025). Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfaf104

Shao, D., Jimenez, A. L., Guerrero, M. S., Wang, S., & Broder, A. (2025). Factors associated with worsening interstitial fibrosis/tubular atrophy in lupus nephritis patients undergoing clinically indicated repeat kidney biopsy. BMC Nephrology, 26(1). https://doi.org/10.1186/s12882-025-04108-0

Bu, L., Valeri, A. M., Said, S. M., Zhu, Y., Hernandez, L. H., Gladish, R., Prasad, B., Sethi, S., Leung, N., & Nasr, S. H. (2025). IgM Variant of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits: A Case Series. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2025.01.009

Rebello, S., Hsu, K., Nativi-Nicolau, J., Karam, C., Grogan, M., Lousada, I., & Maurer, M. S. (2025). Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey. Amyloid, 1–10. https://doi.org/10.1080/13506129.2025.2462541

Blazius, B., Troost, J. P., Kopp, J. B., Parekh, R. S., Gillespie, B., Ayoub, I., Kallash, M., Gbadegesin, R., Canetta, P. A., Srivastava, T., Hunley, T. E., Twombley, K. E., Peleg, Y. A., Greenbaum, L. A., Chishti, A. S., Nester, C. M., Mottl, A. K., Hogan, S. L., Royal, V., … Kidd, J. M. (2025). Clinical Decision-Making About Immunosuppressive Treatment in Focal Segmental Glomerulosclerosis. Kidney Medicine, 7(4), 100975. https://doi.org/10.1016/j.xkme.2025.100975

Simeone, C. A., McNulty, M. T., Gupta, Y., Genovese, G., Sampson, M. G., Sanna-Cherchi, S., Friedman, D. J., & Pollak, M. R. (2024). The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination event. G3: Genes, Genomes, Genetics. https://doi.org/10.1093/g3journal/jkae290

Haruhara, K., Okabayashi, Y., Sasaki, T., Kubo, E., D’Agati, V. D., Bertram, J. F., Tsuboi, N., & Yokoo, T. (2024). Podocyte density as a predictor of long-term kidney outcome in obesity-related glomerulopathy. Kidney International. https://doi.org/10.1016/j.kint.2024.05.025

Zanoni, F., Naesens, M., Leal, R., Amoroso, A., Caliskan, Y., Keating, B., Gharavi, A., Castellano, G., Batal, I., & Kiryluk, K. (2024). #1450 Polygenic risk score of native IgA nephropathy predicts risk of post-transplant disease recurrence. Nephrology Dialysis Transplantation, 39(Supplement_1). https://doi.org/10.1093/ndt/gfae069.184

Fakhouri, F., Bomback, A., Kavanagh, D., Remuzzi, G., Sunder-Plassmann, G., Kanellis, J., Daina, E., Walker, P., Wang, Z., & Ahmad, Z. (2024). #1467 Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 12-week evolution. Nephrology Dialysis Transplantation, 39(Supplement_1). https://doi.org/10.1093/ndt/gfae069.442

Escudero-Saiz, V. J., Gonzalez, Á., García-Herrera, A., Larque, A. B., Bomback, A. S., Morantes, L., Martínez-Chillarón, M., Ollé, J., Guillén, E., Xipell, M., Molina-Andújar, A., Rodríguez, D., Cuadrado, E., Cacho, J., Arana, C., Esforzado, N., Bastida, C., Poch, E., Diekman, F., … Blasco, M. (2024). Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases. Kidney Medicine, 6(6), 100823. https://doi.org/10.1016/j.xkme.2024.100823

Ndife, B., Aldworth, C., Murphy, K. P., Nguyen, J., Pivneva, I., Edwards, M. L., Anderson, A., Signorovitch, J., & Canetta, P. (2024). WCN24-551 CKD PROGRESSION IN PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY (C3G) IN A US MULTI-CENTER ASSESSMENT. Kidney International Reports, 9(4), S244. https://doi.org/10.1016/j.ekir.2024.02.501

Ndife, B., Aldworth, C., Murphy, K. P., Nguyen, J., Pivneva, I., Edwards, M. L., Anderson, A., Signorovitch, J., & Canetta, P. (2024). WCN24-479 CHARACTERISTICS OF PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY (C3G) IN A US MULTI-CENTER ASSESSMENT. Kidney International Reports, 9(4), S243. https://doi.org/10.1016/j.ekir.2024.02.499

DiFranza, L. T., Daniel, E., Serban, G., Thomas, S. M., Santoriello, D., Ratner, L. E., D’Agati, V. D., Vasilescu, E.-R., Husain, S. A., & Batal, I. (2024). Collapsing glomerulopathy is likely a major contributing factor for worse allograft survival in patients receiving kidney transplants from black donors. Frontiers in Medicine, 11. https://doi.org/10.3389/fmed.2024.1369225

Raina, R., Jothi, S., Haffner, D., Somers, M., Filler, G., Vasistha, P., Chakraborty, R., Shapiro, R., Randhawa, P. S., Parekh, R., Licht, C., Bunchman, T., Sethi, S., Mangat, G., Zaritsky, J., Schaefer, F., Warady, B., Bartosh, S., McCulloch, M., … Radhakrishnan, J. (2024). Post-transplant recurrence of focal segmental glomerular sclerosis: consensus statements. Kidney International, 105(3), 450–463. https://doi.org/10.1016/j.kint.2023.10.017

Gbadegesin, R., Martinelli, E., Gupta, Y., Friedman, D. J., Sampson, M. G., Pollak, M. R., & Sanna-Cherchi, S. (2024). APOL1 genotyping is incomplete without testing for the protective M1 modifier p.N264K variant. Glomerular Diseases. Portico. https://doi.org/10.1159/000537948

Duret, L. C., Hamidouche, T., Steers, N. J., Pons, C., Soubeiran, N., Buret, D., Gilson, E., Gharavi, A. G., D’Agati, V. D., & Shkreli, M. (2024). Targeting WIP1 phosphatase promotes partial remission in experimental collapsing glomerulopathy. Kidney International, 105(5), 980–996. https://doi.org/10.1016/j.kint.2024.02.009

Avasare, R. S., Clark, S., Spain, R. I., Wusirika, R., Rope, R., Gurley, S., Stanaway, M., Sekulic, M., Santoriello, D., Bomback, A. S., Canetta, P., Iyer, S. J., Kung, V., Charu, V., Troxell, M. L., Kudose, S., & Andeen, N. K. (2024). Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers. Kidney International Reports, 9(5), 1379–1386. https://doi.org/10.1016/j.ekir.2024.02.1401

Andeen, N. K., DiFranza, L., Kung, V. L., Henriksen, K., Gupta, R., Dinesh, K., Akilesh, S., Kudose, S., Smith, K. D., & Troxell, M. L. (2024). AA amyloidosis With Ig-Dominant Staining and Diagnostically Unusual Features. Kidney International Reports, 9(1), 162–170. https://doi.org/10.1016/j.ekir.2023.10.005

Blasco, M., & Bomback, A. S. (2024). Complement and Podocytopathies: Do We Have a New Biomarker? Kidney International Reports, 9(3), 520–522. https://doi.org/10.1016/j.ekir.2024.01.037

Tarragon Estebanez, B., & Bomback, A. S. (2024). C3 Glomerulopathy: Novel Treatment Paradigms. Kidney International Reports, 9(3), 569–579. https://doi.org/10.1016/j.ekir.2023.12.007

Gupta, Y., Friedman, D. J., McNulty, M. T., Khan, A., Lane, B., Wang, C., Ke, J., Jin, G., Wooden, B., Knob, A. L., Lim, T. Y., Appel, G. B., Huggins, K., Liu, L., Mitrotti, A., Stangl, M. C., Bomback, A., Westland, R., Bodria, M., … Sanna-Cherchi, S. (2023). Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43020-9

Rajasekaran, A., Larkina, M., Julian, B. A., Canetta, P. A., Roehm, B. A., Khalid, M., Mariani, L. H., & Rizk, D. V. (2023). Optimal Conservative Therapy Use among Adult Cure Glomerulonephropathy Participants with IgA Nephropathy. Kidney360, 4(12), 1763–1769. https://doi.org/10.34067/kid.0000000000000306

Peters, D. T., Amburn, J., Tuchman, S., Lichtman, E. I., Jensen, C. E., Jain, K., Lentzsch, S., Chakraborty, R., Bhutani, D., & Rubinstein, S. M. (2023). Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance. Blood, 142(Supplement 1), 2027–2027. https://doi.org/10.1182/blood-2023-189341

Sethi, S., Beck, L. H., Glassock, R. J., Haas, M., De Vriese, A. S., Caza, T. N., Hoxha, E., Lambeau, G., Tomas, N. M., Madden, B., Debiec, H., D’Agati, V. D., Alexander, M. P., Amer, H., Appel, G. B., Barbour, S. J., Caravaca-Fontan, F., Cattran, D. C., Casal Moura, M., … Fervenza, F. C. (2023). Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification. Mayo Clinic Proceedings, 98(11), 1671–1684. https://doi.org/10.1016/j.mayocp.2023.08.006

Sethi, S., Beck, L. H., Glassock, R. J., Haas, M., De Vriese, A. S., Caza, T. N., Hoxha, E., Lambeau, G., Tomas, N. M., Madden, B., Debiec, H., D’Agati, V. D., Alexander, M. P., Amer, H., Appel, G. B., Barbour, S. J., Caravaca-Fontan, F., Cattran, D. C., Casal Moura, M., … Fervenza, F. C. (2023). Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney International, 104(6), 1092–1102. https://doi.org/10.1016/j.kint.2023.06.032

Oliva-Damaso, N., & Bomback, A. S. (2023). Intravenous Methylprednisolone in Induction Therapy for ANCA-Associated Vasculitis: How Low Can We Go? Kidney360, 4(9), e1199–e1200. https://doi.org/10.34067/kid.0000000000000257

Cortazar, F. B., Cerda, J., Dhanani, R., Roglieri, J., & Santoriello, D. (2023). Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis. Kidney International Reports, 8(8), 1687–1691. https://doi.org/10.1016/j.ekir.2023.05.017

Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. HemaSphere, 7(S3), e724362f. https://doi.org/10.1097/01.hs9.0000971248.72436.2f

Marasa, M., Ahram, D. F., Rehman, A. U., Mitrotti, A., Abhyankar, A., Jain, N. G., Weng, P. L., Piva, S. E., Fernandez, H. E., Uy, N. S., Chatterjee, D., Kil, B. H., Nestor, J. G., Felice, V., Robinson, D., Whyte, D., Gharavi, A. G., Appel, G. B., Radhakrishnan, J., … Sanna-Cherchi, S. (2023). Implementation and Feasibility of Clinical Genome Sequencing Embedded Into the Outpatient Nephrology Care for Patients With Proteinuric Kidney Disease. Kidney International Reports, 8(8), 1638–1647. https://doi.org/10.1016/j.ekir.2023.05.021

Kudose, S., Cossey, L. N., Canetta, P. A., Sekulic, M., Vanbeek, C. A., Huls, F. B., Gupta, I., Bu, L., Alexander, M. P., Cornell, L. D., Fidler, M. E., Markowitz, G. S., Larsen, C. P., D’Agati, V. D., Nasr, S. H., & Santoriello, D. (2023). Clinicopathologic Spectrum of Lysozyme-Associated Nephropathy. Kidney International Reports, 8(8), 1585–1595. https://doi.org/10.1016/j.ekir.2023.05.007

See, S. B., Yang, X., Burger, C., Lamarthée, B., Snanoudj, R., Shihab, R., Tsapepas, D. S., Roy, P., Larivière-Beaudoin, S., Hamelin, K., Mendoza Rojas, A., van Besouw, N. M., Bartosic, A., Daniel, N., Rodica, V. E., Mohan, S., Cohen, D., Ratner, L., Baan, C. C., … Zorn, E. (2023). Natural Antibodies Are Associated With Rejection and Long-term Renal Allograft Loss in a Multicenter International Cohort. Transplantation, 107(7), 1580–1592. https://doi.org/10.1097/tp.0000000000004472

Mottl, A. K., Bomback, A. S., Mariani, L. H., Coppock, G., Jennette, J. C., Almaani, S., Gipson, D. S., Kelley, S., Kidd, J., Laurin, L.-P., Mucha, K., Oliverio, A., Palmer, M., Rizk, D., Sanghani, N., Stokes, M. B., Susztak, K., Wadhwani, S., & Nast, C. C. (2023). CureGN-Diabetes Study: Rationale, Design, and Methods of a Prospective Observational Study of Glomerular Disease Patients with Diabetes. Glomerular Diseases, 155–164. Portico. https://doi.org/10.1159/000531679

Perkovic, V., Barratt, J., Radhakrishnan, J., Rizk, D., Trimarchi, H., Khawaja, Z., Leiske, J., Sorensen, B., King, A., Jones-Burton, C., & Campbell, K. (2023). #4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 38(Supplement_1). https://doi.org/10.1093/ndt/gfad063c_4333

Jurczak, W., Lamanna, N., Tam, C. S., Kontos, A., Konig, H., Ruppert, A. S., & Tsai, D. E. (2023). COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematological Oncology, 41(S2), 758–759. Portico. https://doi.org/10.1002/hon.3165_605

Okabayashi, Y., Tsuboi, N., Marumoto, H., Sasaki, T., Haruhara, K., Kanzaki, G., Koike, K., Ueda, H., Shimizu, A., Puelles, V. G., D’Agati, V., & Yokoo, T. (2023). Single-Nephron GFR in Different Glomerular Basement Membrane Stages of Membranous Nephropathy. Kidney360, 4(6), e777–e786. https://doi.org/10.34067/kid.0000000000000142

Bomback, A. (2023). Plain language summary of the design of the APPEAR-C3G Study: A Study to Learn How Well Iptacopan Works in People with Complement 3 Glomerulopathy. Future Rare Diseases, 3(2). https://doi.org/10.2217/frd-2022-0020

Zuo, Y., Navaz, S., Liang, W., Li, C., Ayers, C. R., Rysenga, C. E., Harbaugh, A., Norman, G. L., Solow, E. B., Bermas, B., Akinmolayemi, O., Rohatgi, A., Karp, D. R., Knight, J. S., & de Lemos, J. A. (2023). Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events. JAMA Network Open, 6(4), e236530. https://doi.org/10.1001/jamanetworkopen.2023.6530

Reynolds, M. L., Oliverio, A. L., Zee, J., Hendren, E. M., O’Shaughnessy, M. M., Ayoub, I., Almaani, S., Vasylyeva, T. L., Twombley, K. E., Wadhwani, S., Steinke, J. M., Rizk, D. V., Waldman, M., Helmuth, M. E., Avila-Casado, C., Alachkar, N., Nester, C. M., Derebail, V. K., Hladunewich, M. A., & Mariani, L. H. (2023). Pregnancy History and Kidney Disease Progression Among Women Enrolled in Cure Glomerulonephropathy. Kidney International Reports, 8(4), 805–817. https://doi.org/10.1016/j.ekir.2023.01.036

Mariani, L. H., Eddy, S., AlAkwaa, F. M., McCown, P. J., Harder, J. L., Nair, V., Eichinger, F., Martini, S., Ademola, A. D., Boima, V., Reich, H. N., El Saghir, J., Godfrey, B., Ju, W., Tanner, E. C., Vega-Warner, V., Wys, N. L., Adler, S. G., Appel, G. B., … Kretzler, M. (2023). Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis. Kidney International, 103(3), 565–579. https://doi.org/10.1016/j.kint.2022.10.023

Kallash, M., Wang, Y., Smith, A., Trachtman, H., Gbadegesin, R., Nester, C., Canetta, P., Wang, C., Hunley, T. E., Sperati, C. J., Selewski, D., Ayoub, I., Srivastava, T., Mottl, A. K., Kopp, J., Gillespie, B., Robinson, B., Chen, D., … Steinke, J. (2023). Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clinical Journal of the American Society of Nephrology, 18(3), 344–355. https://doi.org/10.2215/cjn.0000000000000069

Batal, I., Khairallah, P., Weins, A., Andeen, N. K., & Stokes, M. B. (2023). The role of HLA antigens in recurrent primary focal segmental glomerulosclerosis. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1124249

Nester, C., Appel, G. B., Bomback, A. S., Bouman, K. P., Cook, H. T., Daina, E., Dixon, B. P., Rice, K., Najafian, N., Hui, J., Podos, S. D., Langman, C. B., Lightstone, L., Parikh, S. V., Pickering, M. C., Sperati, C. J., Trachtman, H., Tumlin, J., de Vries, A. P., … Remuzzi, G. (2022). Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. American Journal of Nephrology, 53(10), 687–700. Portico. https://doi.org/10.1159/000527167

Kudose, S., Batal, I., Lucia, J., Patel, P., Soni, R. K., Markowitz, G. S., D’Agati, V. D., & Stokes, M. B. (2023). Proliferative Glomerulonephritis With Hidden Monotypic IgG3κ Deposits: A Case Report. American Journal of Kidney Diseases, 81(1), 114–117. https://doi.org/10.1053/j.ajkd.2022.05.018

Podos, S. D., Trachtman, H., Appel, G. B., Bomback, A. S., Dixon, B. P., Wetzels, J. F. M., Cook, H. T., Parikh, S. V., Pickering, M. C., Tumlin, J., Langman, C. B., Lightstone, L., Sperati, C. J., Daina, E., Bouman, K. P., Rice, K., Thanassi, J. A., Huang, M., Nester, C., & Remuzzi, G. (2022). Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. American Journal of Nephrology, 53(10), 675–686. Portico. https://doi.org/10.1159/000527166

DiFranza, L. T., Chafouleas, E., Katipally, S., Stokes, M. B., Kudose, S., & Sekulic, M. (2022). Crescentic Fibrillary Glomerulonephritis in the Setting of Immune Checkpoint Inhibitor Therapy: A Report of Two Cases. Glomerular Diseases, 3(1), 69–74. Portico. https://doi.org/10.1159/000528881

Ravipati, P., Freese, R. L., Royal, V., Bu, L., Canetta, P., Gipson, D., Kallash, M., Kiryluk, K., Nast, C., Reich, H. N., Rheault, M. N., Saha, M., & Nachman, P. H. (2022). Clinicopathologic Significance of Predominant Lambda Light Chain Deposition in IgA Nephropathy. Kidney International Reports, 7(11), 2462–2473. https://doi.org/10.1016/j.ekir.2022.08.003

Bomback, A. S., Kavanagh, D., Vivarelli, M., Meier, M., Wang, Y., Webb, N. J. A., Trapani, A. J., & Smith, R. J. H. (2022). Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. Kidney International Reports, 7(10), 2150–2159. https://doi.org/10.1016/j.ekir.2022.07.004

Jones, A. V., Curtiss, D., Harris, C., Southerington, T., Hautalahti, M., Wihuri, P., Mäkelä, J., Kallionpää, R. E., Makkonen, E., Knopp, T., Mannermaa, A., Mäkinen, E., Moilanen, A.-M., Tezel, T. H., & Waheed, N. K. (2022). An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access. PLOS ONE, 17(9), e0272260. https://doi.org/10.1371/journal.pone.0272260

Floege, J., Gibson, K. L., Praga, M., Radhakrishnan, J., Reich, H. N., Schreuder, M. F., Wetzels, J. F., Tesař, V., Vivarelli, M., Biechele, S., & Tonelli, M. (2022). Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey. Kidney International Reports, 7(9), 2081–2085. https://doi.org/10.1016/j.ekir.2022.06.010